Trial Profile
Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB and stage II non-small cell lung cancer with WT1 antigen positive.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs WT 4869 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2015 Planned End Date changed from 30 Sep 2021 to 6 jul 2015 as reported by University Hospital Medical Information Network - Japan.
- 13 Jul 2015 Status changed from suspended to discontinued as reported by University Hospital Medical Information Network - Japan.
- 14 Aug 2014 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.